🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Henlius signs a licensing deal with a global biopharma to commercialize a proposed ipilimumab #biosimilar across key regulated markets — US, EU, Japan, and more. Read the #news: henlius.com/en/NewsDetails…

#HenliusMedicalHub 🌟HANSIZHUANG shines in two Phase 2 gastric cancer combos: Neoadjuvant + chemoradiotherapy (EGJ)☑️ Triple-threat: PD-1 + thymosin + SOX ☑️”1M+ annual cases” → And more phase 3 trials loading! #CancerResearch Learn More: henlius.com/en/NewsDetails…

🚀 #HenliusinFocus Meet us at #BIO2025 (Booth 1885)!💡Perfect opportunity to discover our game-changers. Experts available to schedule📍Boston | June 16-19 #CancerResearch

#HenliusinFocus Henlius has been included in the #MSCl Global Small Cap Indexes! A milestone recognizing our global growth potential. As a profitable #biopharma (HKEX:2696), we're accelerating worldwide access to innovative therapies.#Innovation Learn More lnkd.in/dtVGJZ5n

#HenliusInFocus HLX13, a #biosimilar candidate of ipilimumab, has dosed its first patient in a Phase 1/3 trial. Stay tuned as we advance more life-changing treatments. Read the #news: henlius.com/en/NewsDetails…

#HenliusMedicalHub🔬#InternationalClinicalTrialsDay Update! 70+ trials approved ✅8,700+ patients globally 🌍30+ trails ongoing 💊Pushing boundaries in: Next-gen biologics & Affordable oncology innovations. Proud of our global #Biotech warriors! 👏

#HenliusinFocus Henlius achieves ISO/IEC 27001:2022 upgrade (CNAS/ANAB/UKAS endorsed) – the gold standard in information security governance. Building trust through: Cybersecurity🌐Cloud security☁️ Privacy safeguards🛡️ Learn More : henlius.com/en/NewsDetails…

#HenliusMedicalHub Join Henlius' Post-ASCO Business Update (June 2, Chicago): 💊Executives & PI insights 🔬 HLX43 (PD-L1 ADC) deep dive 📍 Chicago or virtual 🔗Grab your spot! #ASCO2025

#HenliusMedicalHub Hot off! HLX22, our anti-HER2 mAb, just bagged Orphan Drug Designation in the EU for gastric cancer! 10-year market exclusivity✅ Faster EU rollout with fee cuts & regulatory perks✅ Learn More: henlius.com/en/NewsDetails…

The Next-Gen Biotech Partner? Henlius delivers: Novel therapies 🔬 Global access 🌍 Strategic alliances 🤝 Join us at BIO 2025 Booth #1885, let’s shape healthcare future.

#HenliusinFocus Henlius will present Jefferies in NYC (June 3-5). Our CEO, Jason, will share the latest trends and opportunities in biopharma with 3K+ leaders.🌍#JefferiesHealthcare

#HenliusMedicalHub Breakthroughs from #ASCO25: Updated results on serplulimab—the 1st anti-PD-1 mAb approved for 1L SCLC—showed 4-yr OS rate of 21.9% in 1L ES-SCLC✅ Promising efficacy in 10+ GI cancer studies✅ Pushing boundaries in #CancerResearch. 🔗 henlius.com/en/NewsDetails…

#HenliusMedicalHub 🔥#ASCO 2025 Update! HLX22 shines in HER2+ gastric cancer: ✅ Phase 2: Durable PFS/OS (2+ yrs follow-up) ✅ Phase 3: Global head-to-head trial underway A dual HER2 blockade —Global development for global patients🌏 Learn More: henlius.com/en/NewsDetails…

#HenliusMedicalHub HLX43, our PD-L1-targeting ADC, showed promising phase 1 results at #ASCO25—dual IO+ADC activity, biomarker-agnostic potential, and early efficacy in NSCLC & TSCC. No PD-L1 ADCs approved yet—HLX43 is pushing new frontiers. 🔗henlius.com/en/NewsDetails…

#HenliusInFocus🔬 At #ASCO2025, we brought together oncology legends David Gandara ，Jaffer Ajani，and Fred R. Hirsch to decode our potential first-in-class assets serplulimab, HLX22, and HLX43. Where great minds meet, hope grows. ✨ Read More: henlius.com/en/NewsDetails…

#HenliusInFocus Just rocked the Jefferies Global Healthcare Conference. Our CEO outlined our sprint to the future: Supercharged pipeline✅ Next-gen platforms✅GMP-certified facilities ✅Quality, innovation, and trust – more beyond medicine. Learn More henlius.com/en/NewsDetails…

#HenliusMedicalHub Exciting update! Our PD-L1 ADC, HLX43, completed first subject dosing in a Phase 2 MRCT for NSCLC, following its #ASCO2025 spotlight. Buckle up! This may redefine solid tumor treatment. #Innovation Learn More: henlius.com/en/NewsDetails…

#HenliusInFocus🌏serplulimab is approved in Singapore & Malaysia! 5th SEA markets land (after Indonesia/Thailand/Cambodia)✅ World's 1st anti-PD-1 for 1L SCLC💥110K+ patients treated already🤲Next stop? More lives transformed! #GlobalHealthcare Read more:henlius.com/en/NewsDetails…

#HenliusMedicalHub 🔥 Meet HLX43: Game-Changer ADC! ✅Biomarker barriers breaking✅ ADC + IO dual mechanism✅Encouraging efficacy in NSCLC/TSCC Where limits end, possibilities begin. #CancerResearch #Immunotherapy Watch the video to learn more 👇

Our CEO to Citeline "It’s not our goal to simply pick a dosage below the maximum tolerated dose for later-line treatment only", we are racing to 1L treatment/combo therapy. 🔗: scrip.pharmaintelligence.informa.com/scrip/r-and-d/…